Tradestie Institutional Equity Comparison Engine
ACHV vs ICCC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ICCC Overall Edge
ICCC Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immucell Corp (ICCC) driven by superior Growth & Margin, Momentum & Technical while ACHV counters with relative strength in Valuation, Options & Structure. Fundamentally, ACHV trades at 35.3x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ICCC at N/M Forward P/E and 15.2% operating margin (+11.5% YoY). In options structure, ACHV sits in BREAKOUT (23rd %ile IV; Dealer Gamma Walls on Pro) against ICCC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
ACHV
ACHV 35.3x vs ICCC N/M Fwd P/E
Growth & Margin Winner
ICCC
Op Margin 0.0% vs 15.2% ยท YoY +0.0% vs +11.5%
Momentum & Technical Winner
ICCC
1Y +43.0% vs +88.8% ยท 52W Pos 69% vs 91%
Options & Structure Winner
ACHV
BREAKOUT (23rd %ile IV) vs UNCLASSIFIED (N/A IV)
ACHV
NASDAQ
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap
$692.8M
1M Return
-8.5%
1Y Return
+43.04%
Forward P/E
35.3x
Unified AI Score
56.6 / 100
HOLD
Tech 66.0
Fund 58.0
Flow 57.0
Mom 58.9
ICCC
NASDAQ
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap
$97.7M
1M Return
+6.23%
1Y Return
+88.76%
Forward P/E
N/M
Unified AI Score
43.8 / 100
HOLD
Tech 15.0
Fund 48.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ACHV +43.04%
ICCC +88.76%
Spread: +20.9 pp (ICCC Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ACHV TTM Op. Margin: 0.0%
ICCC TTM Op. Margin: 15.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACHV vs ICCC. Trailing 12-month operating profitability (ACHV 0.0% vs ICCC 15.2%) and valuation multiples (ACHV 35.3x vs ICCC N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ACHV | ICCC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $692.8M | $97.7M | Larger Scale | ACHV |
| Trailing P/E Ratio Valuation | 35.3x | 56.6x | Lower Multiple | ACHV |
| Forward P/E Ratio Valuation | 35.3x | N/M | Lower Multiple | ACHV |
| Revenue Growth (YoY) Growth | +0.0% | +11.5% | Higher Growth | ICCC |
| Operating Margin (TTM) Profitability | 0.0% | 15.2% | Higher Margin | ICCC |
| Net Profit Margin Profitability | 0.0% | 2.6% | Higher Margin | ICCC |
| Return on Equity (ROE) Capital Efficiency | -845.0% | 2.6% | Higher ROE | ICCC |
| 52-Week Range Position Momentum | 69% ($3โ$9) | 91% ($5โ$12) | Stronger Trend | ICCC |
| Beta / 30D Volatility Risk Regime | 1.73ฮฒ ยท 62% Vol | 0.24ฮฒ ยท 46% Vol | Lower Realized Risk | ICCC |
| Unified Institutional Score Composite Signal | 56.6 / 100 (HOLD) | 43.8 / 100 (HOLD) | Higher Composite | ACHV |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ACHV vs ICCC Buy Guide
ACHV
BREAKOUT
125d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
23rd %ile
IV Regime
Compressed (<25th %ile)
ICCC
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ACHV nor ICCC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.